Atea Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
225 Franklin St Ste 2100, Boston, Massac...Phone Number
(857) 284-8891Website
www.ateapharma.comRevenue
-Stock Symbol
AVIRIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
2
2
1
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Explore more
Atea Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atea Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Atea Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Atea Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Atea Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Atea Pharmaceuticals
Check out if Atea Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Atea Pharmaceuticals launches new products
Click to see if Atea Pharmaceuticals had a recent Job posting/layoffs
Atea Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Atea Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Atea Pharmaceuticals
Compare insights from companies similar to Atea Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Atea Pharmaceuticals
51-200
Public
$591M
2012
AC
Andrea CorcoranChief Financial Officer & Executive VP, Legal
Company Profile Activity
Activity Insights
Atea Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Atea Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Atea Pharmaceuticals.
Atea Pharmaceuticals financials insights
Gather financial insights about Atea Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$20M
2016
Unspecified
$20.8M
2018
Unspecified
$27.6M
2019
Series B
$7.6M
2020
Series D
$215M
Stock Offering
$300M
Atea Pharmaceuticals Tech Stack
A closer look at the technologies used by Atea Pharmaceuticals
Most Recent Scoops
Person-Based
Earnings, Finance
Project
Atea Pharmaceuticals has confirmed that C-FORWARD will have two primary endpoints: the modified intent-to-treat (MITT) population analysis as the primary endpoint for the FDA, consistent with C-BEYOND, and a per-protocol analysis as the primary endpoint for the EMA.
Project
Atea Pharmaceuticals has outlined near-term milestones including an anticipated NDA submission in Q2 2027 pending positive C-FORWARD results, advancement of its Hepatitis E program toward proof of concept in 2027, and an expected short time to profitability following an anticipated mid-2028 launch of bemnifosbuvir.
Pharmaceuticals, Clinical Operations
Project
Atea Pharmaceuticals has reported that the C-BEYOND trial enrolled a real-world HCV patient population in which more than half reported injection drug use as the root of HCV transmission, approximately 89% were taking concomitant medications, two-thirds had a psychiatric disorder, and over 10% prematurely discontinued treatment, were lost to follow-up, or were non-adherent to the protocol.
Project
Product Launch, Manufacturing Operations
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Atea Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develop... Read More
